OncoZenge AB (publ) reported earnings results for the fourth quarter and full year ended December 31, 2023. For the fourth quarter, the company reported revenue was SEK 0.003 million compared to SEK 0.001 million a year ago. Net loss was SEK 3.17 million compared to SEK 4.56 million a year ago. Basic loss per share from continuing operations was SEK 0.27 compared to SEK 0.39 a year ago. Diluted loss per share from continuing operations was SEK 0.27 compared to SEK 0.39 a year ago.
For the full year, revenue was SEK 0.003 million. Net loss was SEK 15.9 million compared to SEK 46.65 million a year ago. Basic loss per share from continuing operations was SEK 1.36 compared to SEK 3.98 a year ago.